CN102015691B - 作为活化素样受体激酶(alk4或alk5)抑制剂的咪唑并吡啶衍生物 - Google Patents

作为活化素样受体激酶(alk4或alk5)抑制剂的咪唑并吡啶衍生物 Download PDF

Info

Publication number
CN102015691B
CN102015691B CN200980115503.0A CN200980115503A CN102015691B CN 102015691 B CN102015691 B CN 102015691B CN 200980115503 A CN200980115503 A CN 200980115503A CN 102015691 B CN102015691 B CN 102015691B
Authority
CN
China
Prior art keywords
pyridine
pyridin
imidazo
base
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980115503.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102015691A (zh
Inventor
C·勒布朗
C·里奇
D·肖
N·J·施蒂夫尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN102015691A publication Critical patent/CN102015691A/zh
Application granted granted Critical
Publication of CN102015691B publication Critical patent/CN102015691B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
CN200980115503.0A 2008-04-29 2009-04-27 作为活化素样受体激酶(alk4或alk5)抑制剂的咪唑并吡啶衍生物 Expired - Fee Related CN102015691B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08155405 2008-04-29
EP08155405.7 2008-04-29
PCT/EP2009/055066 WO2009133070A1 (en) 2008-04-29 2009-04-27 Imidazo-pyridine derivatives as activin-like receptor kinase (alk4 or alk5) inhibitors

Publications (2)

Publication Number Publication Date
CN102015691A CN102015691A (zh) 2011-04-13
CN102015691B true CN102015691B (zh) 2014-01-08

Family

ID=40043988

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980115503.0A Expired - Fee Related CN102015691B (zh) 2008-04-29 2009-04-27 作为活化素样受体激酶(alk4或alk5)抑制剂的咪唑并吡啶衍生物

Country Status (14)

Country Link
US (1) US9079897B2 (https=)
EP (1) EP2307402B1 (https=)
JP (1) JP5507543B2 (https=)
KR (1) KR20100130226A (https=)
CN (1) CN102015691B (https=)
AU (1) AU2009242145B2 (https=)
BR (1) BRPI0911490A2 (https=)
CA (1) CA2722131A1 (https=)
EA (1) EA201001687A1 (https=)
ES (1) ES2399175T3 (https=)
MX (1) MX2010011867A (https=)
PL (1) PL2307402T3 (https=)
PT (1) PT2307402E (https=)
WO (1) WO2009133070A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012018954A2 (pt) 2010-02-05 2016-04-12 Merck Patent Gmbh derivados de hetaril-[1,8]naftiridina
SG183233A1 (en) 2010-02-22 2012-09-27 Merck Patent Gmbh Hetarylaminonaphthyridines
US9073918B2 (en) 2010-05-20 2015-07-07 Takeda Pharmaceutical Company Limited Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
WO2012064043A2 (ko) 2010-11-08 2012-05-18 에스케이케미칼 주식회사 폴리유산 수지, 이의 제조 방법 및 이를 포함하는 포장용 필름
AU2012240656A1 (en) * 2011-04-05 2013-10-24 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Compounds and methods for altering activin receptor-like kinase signalling
JP2016510764A (ja) 2013-03-07 2016-04-11 カリフィア バイオ, インク.Califia Bio, Inc. 混合系キナーゼ阻害剤および治療法
US10179777B2 (en) 2015-04-16 2019-01-15 Merck Patent Gmbh 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives
US10508082B2 (en) * 2015-09-23 2019-12-17 Dana-Farber Cancer Institute, Inc. Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPK
RU2642456C2 (ru) * 2016-06-29 2018-01-25 Федеральное государственное бюджетное образовательное учреждение высшего образования "Ярославский государственный университет им. П.Г. Демидова" Способ получения N-арилзамещенных 3H-имидазо[4,5-b]пиридинов
JP7007359B2 (ja) 2016-07-29 2022-01-24 シャンハイ インリ ファーマシューティカル カンパニー リミティド 窒素含有芳香族複素環式化合物、その製造方法、薬物組成物および使用
CN106831770A (zh) * 2017-03-13 2017-06-13 牡丹江医学院 一种药物组合物及其用于治疗肝硬化的用途
CN110066277B (zh) 2018-01-24 2021-07-23 上海璎黎药业有限公司 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用
CN110066276B (zh) 2018-01-24 2020-09-18 上海璎黎药业有限公司 芳香杂环化合物、其中间体、制备方法、药物组合物和应用
US20200247812A1 (en) * 2018-07-10 2020-08-06 Integral Biosciences Private Limited Heterocyclic compounds and methods of use
MX2021003904A (es) * 2018-10-05 2021-10-26 Annapurna Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj.
JP2023509760A (ja) 2020-01-08 2023-03-09 シンシス セラピューティクス，インコーポレイテッド Ａｌｋ５阻害剤複合体およびその使用
US20230174620A1 (en) 2020-04-28 2023-06-08 Acceleron Pharma Inc. Actrii proteins and use in treating post-capillary pulmonary hypertension
EP4182308B1 (en) 2020-07-15 2024-09-04 Chiesi Farmaceutici S.p.A. Pyridazinyl amino derivatives as alk5 inhibitors
EP4182323B1 (en) 2020-07-15 2024-04-24 Chiesi Farmaceutici S.p.A. Pyrido oxazine amino derivatives as alk5 inhibitors
ES2982017T3 (es) 2020-07-15 2024-10-14 Chiesi Farm Spa Derivados de pirido-oxazina como inhibidores de ALK5
EP4267584A1 (en) 2020-12-23 2023-11-01 Chiesi Farmaceutici S.p.A. Pyrido oxazine derivatives as alk5 inhibitors
US20250011299A1 (en) 2021-09-21 2025-01-09 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors
EP4514802A1 (en) 2022-04-27 2025-03-05 Chiesi Farmaceutici S.p.A. Imidazole derivatives as alk5 inhibitors
CN121712526A (zh) 2023-06-13 2026-03-20 辛瑟斯治疗股份有限公司 抗cd5抗体及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563001A1 (en) * 1992-03-26 1993-09-29 Neurosearch A/S Imidazole compounds, their preparation and use
WO2001018000A1 (en) * 1999-09-07 2001-03-15 Merck Sharp & Dohme Limited Imidazo-pyridine derivatives as ligands for gaba receptors
WO2004013138A2 (en) * 2002-07-31 2004-02-12 Smithkline Beecham Corporation Imidazo`1,2-a!pyridines
WO2008006583A1 (en) * 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023246A1 (en) * 2003-09-04 2005-03-17 Aventis Pharmaceuticals Inc. Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp)
CN101052640B (zh) * 2004-09-03 2011-05-11 默克雪兰诺有限公司 吡啶亚甲基唑烷酮类及其作为磷酸肌醇抑制剂的用途
JP2010508315A (ja) * 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563001A1 (en) * 1992-03-26 1993-09-29 Neurosearch A/S Imidazole compounds, their preparation and use
WO2001018000A1 (en) * 1999-09-07 2001-03-15 Merck Sharp & Dohme Limited Imidazo-pyridine derivatives as ligands for gaba receptors
WO2004013138A2 (en) * 2002-07-31 2004-02-12 Smithkline Beecham Corporation Imidazo`1,2-a!pyridines
WO2008006583A1 (en) * 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A concise synthesis of quinazolinone TGF-b RI inhibitor through one-pot three-component Suzuki–Miyaura/etherification and imidate–amide rearrangement reactions;Hong-yu Li, et al.;《Tetrahedron》;20070826;第63卷;第11763-11770页 *
Synthesis and biological evaluation of novel 2,4,5-triaryl-1H-pyrazol-3(2H)-ones as inhibitors of ALK5;Xing Zhou Li, et al.;《Chinses Chemical letters 》;20081231;第19卷;第379-382页 *

Also Published As

Publication number Publication date
JP2011518856A (ja) 2011-06-30
US20110060004A1 (en) 2011-03-10
JP5507543B2 (ja) 2014-05-28
CA2722131A1 (en) 2009-11-05
KR20100130226A (ko) 2010-12-10
AU2009242145A1 (en) 2009-11-05
PT2307402E (pt) 2013-02-15
ES2399175T3 (es) 2013-03-26
MX2010011867A (es) 2010-11-26
US9079897B2 (en) 2015-07-14
EP2307402B1 (en) 2012-11-07
BRPI0911490A2 (pt) 2016-01-05
CN102015691A (zh) 2011-04-13
EA201001687A1 (ru) 2011-06-30
WO2009133070A1 (en) 2009-11-05
AU2009242145B2 (en) 2012-07-05
EP2307402A1 (en) 2011-04-13
PL2307402T3 (pl) 2013-05-31

Similar Documents

Publication Publication Date Title
CN102015691B (zh) 作为活化素样受体激酶(alk4或alk5)抑制剂的咪唑并吡啶衍生物
ES2393430T3 (es) Derivados de imidazo[1,2-A]-piridina útiles como inhibidores de ALK
ES2442930T3 (es) Pirimidinas como inhibidores de cinasas
ES2393932T3 (es) Derivados de Pirimidina como inhibidores de ALK-5
JP5090528B2 (ja) ＡＬＫ４またはＡＬＫ５が介在する疾患を処置するための２、３、７位置換イミダゾ［１，２−ｂ］ピリダジン類
JP5566909B2 (ja) ピリジン誘導体
JP2010508315A (ja) 抗炎症剤としてのヘテロ環式化合物
EP1878733A1 (en) Pyrimidine derivatives as ALK-5 inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Basel

Applicant after: Novartis Ag

Address before: Basel

Applicant before: Novartis AG

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: NOVARTIS AG TO: NOVARTIS CO., LTD.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140108

Termination date: 20170427